Community-Acquired Pneumonia

• Aspiration and microbial colonization of the alveoli: Normal upper airway colonization is rapidly cleared by mucociliary clearance, cough reflex, and IgA-mediated immunity. When the inoculum overwhelms these defenses (large aspiration volume, decreased consciousness, or diminished cough reflex) or when organisms have enhanced virulence factors, bacteria establish infection in the distal airways and alveolar spaces. S. pneumoniae produces pneumolysin, a cholesterol-dependent cytolysin that directly damages epithelial cell membranes and increases vascular permeability. H. influenzae expresses lipooligosaccharide (LOS) that mimics human cell surface structures, evading antibody recognition and enhancing biofilm formation.

• Inflammatory cascade and alveolar-capillary barrier dysfunction: Bacterial lipopolysaccharides (LPS), peptidoglycans, and other pathogen-associated molecular patterns (PAMPs) engage pattern recognition receptors (TLRs, NOD-like receptors) on resident alveolar macrophages and epithelial cells. This triggers robust NF-κB and MAPK signaling, driving production of TNF-α, IL-1β, IL-6, IL-8, and other pro-inflammatory cytokines. While these cytokines recruit neutrophils essential for bacterial clearance (via CXCL8/CXCR2 axis), excessive inflammation causes neutrophil-mediated tissue damage through release of elastase, collagenase, and reactive oxygen species. This inflammatory response increases alveolar-capillary permeability through tight junction disruption (via claudin and occludin degradation), leading to interstitial and alveolar edema. The physiologic consequence is ventilation-perfusion (V/Q) mismatch: consolidated, fluid-filled alveoli remain perfused but cannot participate in gas exchange, creating true pulmonary shunt physiology with resultant hypoxemia that does not respond fully to supplemental oxygen.

• Impaired gas exchange and systemic hypoxia: Beyond local V/Q mismatch, diffuse alveolar damage causes loss of the normal surfactant-producing type I pneumocytes (which comprise ~95% of alveolar surface area). Loss of surfactant leads to increased surface tension, alveolar collapse (atelectasis), and further worsening of shunt physiology. In severe cases, the inflammatory cascade progresses to acute respiratory distress syndrome (ARDS) characterized by protein-rich pulmonary edema, hyaline membrane formation, and widespread alveolar epithelial necrosis. Simultaneously, direct endothelial injury and tissue factor expression on monocytes activate the extrinsic coagulation cascade, increasing risk of thromboembolism and disseminated intravascular coagulation (DIC) in severe pneumonia.

• Bacterial dissemination and systemic inflammation (sepsis pathophysiology): When local immune responses fail to contain infection at the alveolar level, bacteria or bacterial products enter the bloodstream, triggering systemic inflammation through release of PAMPs and damage-associated molecular patterns (DAMPs). LPS engagement of TLR4 on monocytes, dendritic cells, and endothelial cells drives production of TNF-α and IL-1β, which increase vascular endothelial permeability through VE-cadherin disruption and increase expression of adhesion molecules (ICAM-1, VCAM-1). This pathologic vasodilation, increased microvascular permeability, and activation of the contact system (kallikrein-bradykinin pathway) lead to distributive shock with relative hypovolemia despite normal intravascular volume. Concurrent activation of the coagulation cascade through tissue factor exposure can progress to sepsis-induced coagulopathy. These systemic effects drive the clinical syndrome of sepsis with fever, tachycardia, hypotension, altered mental status, and end-organ dysfunction.

• Host immune response variation and disease severity: Individual genetic variation in innate immune signaling (including polymorphisms in TLR4, TNF-α promoter, and IL-10 loci) and adaptive immune capacity (prior pneumococcal vaccination, pneumococcal serotype-specific antibodies) significantly influence disease severity. Patients with impaired opsonization (asplenia, complement deficiencies, hypogammaglobulinemia) are susceptible to overwhelming infection with encapsulated organisms. Those with neutropenia (<500 cells/μL) or defects in neutrophil oxidative burst (chronic granulomatous disease) cannot mount effective granulocytic responses and suffer higher mortality despite antibiotic therapy. Additionally, immunosenescence in elderly patients results in diminished T-cell repertoire and reduced antibody responses, explaining the age-related increase in CAP incidence and severity.

• Streptococcus pneumoniae (pneumococcus): Remains the most common bacterial cause of CAP in most populations, accounting for 20-50% of bacteremic pneumonias. This gram-positive diplococcus has a polysaccharide capsule (>90 serotypes, with serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F causing ~75% of invasive disease) that is antigenically variable and only partially covered by current pneumococcal vaccines (PCV13, PCV20, PPSV23). Risk factors include extremes of age, asplenia, COPD, chronic heart disease, diabetes mellitus, and alcoholism. Pneumococcal disease carries particular significance on board exams due to vaccine-preventable status and evolving antibiotic resistance patterns.

• Haemophilus influenzae (typically non-typeable strains, Nthi): Gram-negative coccobacillus causing 5-10% of CAP, particularly in patients with COPD where increased airway colonization and impaired mucociliary clearance predispose to infection. While Hib (type b) has become rare in vaccinated populations, non-typeable strains produce β-lactamase in ~30% of isolates, necessitating broader empiric coverage. H. influenzae is notable for its ability to form biofilms and cause chronic airway infection.

• Atypical pathogens (Mycoplasma pneumoniae, Chlamydia pneumoniae, Legionella pneumophila): Account for 5-15% of CAP cases and are particularly important because they are not covered by β-lactam antibiotics. Mycoplasma pneumoniae causes epidemic CAP in young adults and healthcare workers, transmitted via respiratory droplets with incubation period of 2-3 weeks. Chlamydia pneumoniae causes insidious illness often preceded by upper respiratory symptoms and is associated with wheezing and bronchitis-like presentations. Legionella pneumophila presents with prominent extrapulmonary features (relative bradycardia, gastrointestinal symptoms, hyponatremia, elevated transaminases) and occurs in outbreaks related to contaminated water systems (air conditioning units, hot tubs, fountains). Atypical pathogens are covered mnemonically as "CHAMP" (Chlamydia, H. influenzae [when resistant], Atypicals, Mycoplasma, Psittacosis/Chlamydia psittaci).

• Gram-negative enteric organisms (Enterobacteriaceae, Pseudomonas aeruginosa): Occur in specific populations with enhanced risk, including those with severe underlying lung disease (cystic fibrosis, bronchiectasis), prolonged hospitalization with prior antibiotics, mechanical ventilation, or immunosuppression (HIV/AIDS with CD4 <50, chemotherapy). P. aeruginosa is particularly important in cystic fibrosis patients and those with COPD and recent hospitalization or high-dose corticosteroid use. These organisms are innately resistant to many β-lactams and require anti-pseudomonal agents (piperacillin-tazobactam, carbapenems, fluoroquinolones).

• Viruses (influenza A/B, RSV, parainfluenza, coronavirus, rhinovirus, adenovirus): Cause community-acquired pneumonia in 15-30% of cases, often presenting with more gradual symptom onset and prominent upper respiratory prodrome. Viral CAP frequently occurs as a primary pathogen but can predispose to secondary bacterial superinfection through damage to airway epithelial defenses and depression of mucociliary clearance. Influenza and coronavirus (SARS-CoV-2) carry higher mortality and risk for ARDS.

• Mixed infections (polymicrobial): Occur in 5-10% of hospitalized CAP cases, particularly with aspiration risk and involving oral anaerobes (Peptostreptococcus, Prevotella, Fusobacterium species).

Risk factors and epidemiologic associations

• Advanced age: Incidence rises exponentially after age 65, with annual incidence ~15-20 per 1,000 in those >85 years. Immunosenescence, increased functional asplenia, and higher rates of chronic comorbidities drive this age association.

• Chronic lung disease (COPD): 10-15% of COPD patients develop CAP annually. Impaired mucociliary clearance, altered airway bacterial ecology toward pathogenic organisms, and increased susceptibility to P. aeruginosa characterize COPD-related CAP.

• Chronic heart disease and cardiovascular comorbidities: Significantly increase CAP risk and mortality through impaired immune function and increased aspiration risk. Heart failure particularly predisposes through pulmonary edema and aspiration.

• Diabetes mellitus: Impaired neutrophil oxidative burst and impaired IL-1 production increase severity and risk of complications including necrotizing infections.

• Chronic kidney disease and end-stage renal disease: Uremic suppression of immune function and increased aspiration risk. Patients on dialysis show altered bacterial flora.

• Asplenia or functional asplenia (sickle cell disease, post-splenectomy): Loss of the spleen's critical role in clearance of opsonized bacteria (particularly S. pneumoniae and H. influenzae type b) results in markedly increased risk of overwhelming sepsis with encapsulated organisms.

• Immunosuppression (HIV/AIDS, chemotherapy, solid organ transplantation, biologics): Specific CD4 count categories predict pathogen risk in HIV (CD4 <200 = PCP risk; CD4 <50 = mycobacterial, fungal, and opportunistic risks). Neutropenic patients (<500 cells/μL) are susceptible to Pseudomonas and fungal infections.

• Active smoking and chronic alcoholism: Both impair mucociliary clearance and neutrophil function, increasing risk for typical pathogens and aspiration pneumonia with anaerobes.

• Aspiration risk factors: Altered mental status (stroke, dementia, medications), dysphagia, gastroesophageal reflux disease (GERD), and conditions predisposing to large-volume aspiration (seizures, general anesthesia).

• Recent antibiotics or hospitalization: Increase likelihood of resistant pathogens including MRSA and P. aeruginosa through selection pressure and altered microbiota.

• Cough: The most common symptom, occurring in >90% of patients. The cough reflects irritation of airways and parenchymal inflammation and may evolve from nonproductive (early) to productive of purulent sputum (later). Rust-colored sputum suggests pneumococcal pneumonia with hemorrhagic edema. Hemoptysis, while uncommon, suggests tissue damage and is seen with necrotizing infections (particularly staphylococcal), anaerobic infections, or cavitary disease (tuberculosis).

• Dyspnea: Occurs in 60-75% of patients and reflects multiple mechanisms: hypoxemia from V/Q mismatch, decreased lung compliance from alveolar edema, tachypnea driving sense of breathlessness, and anxiety. Rapid progression of dyspnea should prompt evaluation for life-threatening complications (empyema, pneumothorax, ARDS). The absence of dyspnea in severe CAP may reflect altered mental status and is an ominous sign.

• Fever and rigors: Occur in 50-70% of patients due to inflammatory cytokine production and bacterial pyrogenic toxins. High fever (>39°C/102°F) is more common with S. pneumoniae and other typical bacteria, while atypical pathogens often produce more modest fever. Notably, absence of fever does not exclude CAP and is particularly common in elderly patients, immunosuppressed patients, and those with severe sepsis (where pyrogenic cytokine response may be masked by compensatory anti-inflammatory response).

• Pleuritic chest pain: Reflects pleural inflammation when consolidation extends to the visceral pleura. Thoracic wall or musculoskeletal chest pain from vigorous coughing may mimic cardiac ischemia.

• Constitutional symptoms: Malaise, fatigue, myalgias, and arthralgia reflect systemic inflammatory response. Prominent myalgias suggest influenza or other viral pneumonia.

• Gastrointestinal symptoms: Nausea, vomiting, and diarrhea occur in 20-30% of CAP cases, more commonly with Legionella (which is associated with watery diarrhea and hepatitis-like pattern) and viral pneumonias.

• Altered mental status: A concerning manifestation indicating severe systemic infection or hypoxemia, particularly in elderly patients where delirium may be the only presenting symptom. Reflects hypoxemia, hypercapnia, metabolic derangements, or direct CNS effects of inflammatory mediators.

Physical examination findings

• Vital sign abnormalities: Fever (typically 38-39°C), tachycardia (often exceeding 100 bpm, with relative bradycardia suggesting atypical pneumonia or certain gram-negatives like Legionella), tachypnea (respiratory rate >20 breaths/min indicates more severe disease, with rates >30 suggesting severe pneumonia or ARDS), and hypoxemia (SpO2 <90% on room air or PaO2 <60 mmHg).

• Adventitious lung sounds: Crackles (rales) represent opening of previously collapsed alveoli and are the most common auscultatory finding, typically heard over consolidated areas in early pneumonia before consolidation becomes "silent." Crackles may be fine (inspiratory, high-pitched, associated with pulmonary edema or interstitial disease) or coarse (lower-pitched, associated with secretions in larger airways). Bronchial breath sounds indicate areas of consolidation with air bronchograms. Decreased breath sounds suggest pleural effusion, pneumothorax, or obstruction. Wheezing may indicate associated bronchitis or atypical pneumonia with airway involvement.

• Percussion findings: Dullness to percussion over consolidated lung indicates consolidation; hyperresonance suggests pneumothorax.

• Egophony and pectoriloquy: Whispered "ee" sounds like "ay" (egophony) and whispered speech transmitted clearly (pectoriloquy) indicate consolidation with enhanced transmission of sound through fluid-filled lung.

• Hepatic tenderness: Particularly with Legionella, reflecting direct hepatitis from infection or systemic inflammation.

• Sepsis-related findings: Hypotension, altered mental status, skin mottling, and cyanosis indicate septic shock requiring intensive management.

Clinical variants

• Atypical pneumonia presentation: Associated with Mycopl

Establishing the diagnosis

• Chest radiography (initial and effectively confirmatory): The 2019 IDSA/ATS CAP guideline defines CAP as compatible symptoms plus a demonstrable infiltrate on imaging. Lobar consolidation with air bronchograms suggests typical bacterial disease; patchy bilateral interstitial/reticulonodular opacities suggest atypical or viral disease. A bulging fissure from inflammatory exudate is the classic Klebsiella finding; cavitation implies necrotizing infection (S. aureus, anaerobes, Klebsiella, TB).
• CT chest: More sensitive than plain film; use when the radiograph is negative but suspicion is high (early disease, neutropenia, dehydration) or when abscess, empyema, or obstructing lesion is suspected.
• Pulse oximetry / ABG: Hypoxemia out of proportion to findings reflects shunt physiology. Hypoxemia that fails to correct with high-FiO2 supplemental oxygen, with a persistently widened A–a gradient, supports true shunt.

Microbiologic workup (severity-driven, per IDSA/ATS 2019)

• Outpatients: No routine sputum culture, blood cultures, or urinary antigens — empiric therapy is standard.
• Severe CAP, or empiric MRSA/Pseudomonas coverage, or prior isolation of those organisms: Obtain blood cultures and sputum Gram stain/culture before antibiotics, plus pneumococcal and Legionella serogroup 1 urinary antigens. Legionella grows on buffered charcoal yeast extract agar with cysteine and iron.
• Influenza/SARS-CoV-2 PCR: Recommended during circulating season, since a positive result changes therapy.
• Procalcitonin: IDSA/ATS explicitly states it should not be used to withhold initial empiric antibiotics; it may support de-escalation.

Severity scoring

• CURB-65: Confusion, Urea (BUN elevated), Respiratory rate ≥30, Blood pressure low, age ≥65 — higher scores drive admission; 0–1 generally supports outpatient care.
• Pneumonia Severity Index (PSI/PORT): Preferred by IDSA/ATS over CURB-65 for the admission decision.
• IDSA/ATS severe CAP criteria: One major criterion (septic shock on vasopressors, or mechanical ventilation) or three minor criteria (including RR ≥30, multilobar infiltrates, confusion, uremia, leukopenia, hypothermia, hypotension needing aggressive fluids) defines ICU-level disease.
• Thoracentesis: Perform for effusions of significant size; pH <7.20, low glucose, or organisms on Gram stain marks a complicated effusion needing drainage.

Immediate stabilization

• Oxygen and airway support: Titrate supplemental oxygen; escalate to high-flow nasal cannula or intubation for refractory hypoxemia or ARDS physiology.
• Sepsis bundle: For hypotension or lactate elevation, give balanced crystalloid resuscitation and start vasopressors (norepinephrine first-line) per Surviving Sepsis Campaign; obtain cultures and give antibiotics promptly rather than waiting for results.

Empiric antibiotics (IDSA/ATS 2019)

• Healthy outpatient, no comorbidities: Aminopenicillin (high-dose amoxicillin) or a tetracycline (doxycycline); a macrolide (azithromycin) only where local pneumococcal macrolide resistance is low.
• Outpatient with comorbidities (COPD, diabetes, heart/liver/kidney disease, alcohol use, asplenia, recent antibiotics): Beta-lactam (amoxicillin-clavulanate or cefpodoxime) plus a macrolide or doxycycline, or respiratory fluoroquinolone monotherapy (levofloxacin, moxifloxacin).
• Inpatient, non-severe: Beta-lactam (ceftriaxone or ampicillin-sulbactam) plus macrolide, or respiratory fluoroquinolone.
• Severe/ICU CAP: Beta-lactam plus either a macrolide or a fluoroquinolone — monotherapy is not adequate.

Escalation

• MRSA coverage: Vancomycin or linezolid, added only for prior MRSA respiratory isolation or locally validated risk factors (post-influenza necrotizing pneumonia, severe CAP with gram-positive cocci in clusters). Vancomycin is dosed to a 24-hour AUC targeting AUC/MIC 400–600 (2020 IDSA/ASHP consensus).
• Pseudomonal coverage: Antipseudomonal beta-lactam (piperacillin-tazobactam, cefepime, meropenem) for prior isolation, bronchiectasis, or structural lung disease.
• Influenza: Neuraminidase inhibitor (oseltamivir) for hospitalized patients regardless of symptom duration; antibacterials are continued because bacterial co-infection cannot be excluded.

Definitive/procedural

• Chest tube drainage for empyema or complicated parapneumonic effusion, with intrapleural fibrinolytic/DNase therapy for loculations and VATS decortication for failure.

Avoid

• The retired "HCAP" category — IDSA/ATS 2019 abandoned it; do not broaden coverage on hospitalization history alone.
• Routine anaerobic coverage for suspected aspiration unless abscess or empyema is present.
• Routine corticosteroids in non-severe CAP (IDSA/ATS 2019 recommends against); the role of corticosteroids in severe CAP and septic shock has been revisited by post-2019 critical-care literature and remains an area of active guideline change. Steroids are not recommended in influenza pneumonia, where they have been associated with harm.
• Stopping too early: minimum 5 days and clinical stability before discontinuation.

Pulmonary and pleural

• Parapneumonic effusion → empyema (emergency): Inflammatory pleural exudate becomes infected and loculated; fibrin deposition traps pus. Signal: persistent fever on appropriate antibiotics, layering effusion, pleural pH <7.20 or purulent fluid. Requires drainage — antibiotics alone fail.
• Lung abscess / necrotizing pneumonia: Tissue destruction from anaerobes, S. aureus (Panton-Valentine leukocidin strains), or Klebsiella. Signal: cavitation with air-fluid level, foul-smelling sputum, hemoptysis.
• ARDS (emergency): Cytokine-driven alveolar-capillary barrier failure with protein-rich edema; bilateral opacities with severe hypoxemia not explained by heart failure. Manage with low-tidal-volume ventilation.
• Respiratory failure requiring intubation: Rising respiratory rate with a normalizing PaCO2 signals fatigue, not improvement.

Systemic

• Bacteremia and septic shock (emergency): Distributive shock from PAMP-driven vasodilation and capillary leak; hypotension refractory to fluids, lactate elevation, mottling.
• Metastatic pneumococcal infection: Meningitis, endocarditis, and septic arthritis — the classic Austrian triad is pneumonia, endocarditis, and meningitis, seen in alcohol use disorder and asplenia.
• Hyponatremia: SIADH, characteristically with Legionella; also transaminitis and diarrhea in that infection.
• Cardiovascular events: Acute MI, new atrial fibrillation, and decompensated heart failure are increased during and after pneumonia through inflammatory plaque destabilization and demand ischemia.

Treatment-related

• Clostridioides difficile colitis: Antibiotic disruption of colonic flora; new watery diarrhea with leukocytosis after fluoroquinolone, clindamycin, or cephalosporin exposure.
• Fluoroquinolone toxicity: Tendinopathy/Achilles rupture, QT prolongation, peripheral neuropathy, CNS effects, dysglycemia, and FDA-labeled aortic aneurysm/dissection risk.
• Vancomycin acute kidney injury: Risk rises with supratherapeutic AUC exposure and is amplified when combined with piperacillin-tazobactam; watch creatinine trend.
• Macrolide QT prolongation: Additive with other QT-prolonging drugs; risk of torsades.
• Beta-lactam hypersensitivity: Cephalosporin cross-reactivity in penicillin allergy is roughly 1–3%, driven by shared R1 side chains — not the beta-lactam ring.

• Chest radiograph is the single best next step in a patient with fever, cough, and focal crackles or egophony — imaging, not empiric antibiotics alone, defines CAP.
• ***Rust-colored sputum* = S. pneumoniae; *currant-jelly sputum* with a bulging fissure in an alcohol-use-disorder patient = Klebsiella pneumoniae**; foul-smelling sputum with a cavity = anaerobic aspiration abscess (dependent segments: right lower lobe superior segment if supine).
• Legionella is the extrapulmonary pneumonia: high fever with relative bradycardia, diarrhea, transaminitis, and hyponatremia. Best initial test is the urinary antigen (serogroup 1 only); culture requires buffered charcoal yeast extract agar with cysteine and iron. A beta-lactam alone will fail because Legionella is an intracellular pathogen (replicating in the alveolar macrophage phagosome) that beta-lactams cannot reach, and most strains produce beta-lactamase — treat with a macrolide (azithromycin) or a respiratory fluoroquinolone. Contrast with Mycoplasma, which truly has no cell wall.
• Mycoplasma buzzwords: young adult in a barracks or dormitory, walking pneumonia with chest film worse than the exam, cold agglutinins causing IgM-mediated hemolysis, and bullous myringitis. Treat with a macrolide or doxycycline; it lacks a cell wall entirely, so beta-lactams are useless.
• Post-influenza pneumonia that turns necrotizing points to Staphylococcus aureus (including PVL-producing MRSA) — this is the setting where adding vancomycin or linezolid is justified.
• The examiners' association: asplenia/sickle cell disease → overwhelming encapsulated organism sepsis (S. pneumoniae first). Confirm vaccination per CDC/ACIP pneumococcal recommendations.
• Common distractor 1: broadening to MRSA/antipseudomonal coverage simply because the patient was recently hospitalized. The HCAP category was retired by the IDSA/ATS 2019 guideline — broaden only for prior isolation or validated local risk factors.
• Common distractor 2: using procalcitonin to justify withholding initial antibiotics, or repeating a chest radiograph at day 3 to "prove" improvement. Radiographic clearance lags clinical recovery by weeks; a follow-up film matters mainly in smokers/older adults to exclude an obstructing malignancy.
• Persistent fever on correct antibiotics = look for empyema, abscess, or a resistant organism — image the pleural space.